By Ben Hirschler LONDON (Reuters) - AstraZeneca took a major step to build up its respiratory medicine business on Wednesday by striking a deal worth up to $2.1 billion for the rights to Spanish group Almirall's lung drugs. The British drugmaker, which resisted a $118 billion takeover attempt by Pfizer in May, said it would pay an initial $875 million and up to $1.22 billion more if the drugs meet development and sales targets. The tie-up boosts a key therapeutic area for AstraZeneca, whose Chief Executive Pascal Soriot is determined to show his company has a strong independent future. Soriot also struck a clinical trial collaboration with Japan's Kyowa Hakko Kirin for a study that will evaluate a combination of the two companies' drugs in cancer - another important field for AstraZeneca.
via Health News Headlines - Yahoo News http://ift.tt/XdAvhv
No comments:
Post a Comment